Physician profile
Mary D Moller
NPI 1770582884
$525,767.04
in general payments reported to CMS, 2019-2025
16 companies · $175K in 2025
The $175K reported for 2025 was more than what 99% of Psychiatric/Mental Health, Adult (Clinical Nurse Specialist) providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $33K · 2022: $54K · 2023: $127K · 2024: $137K · 2025: $175K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $291K · Travel and Lodging: $82K · Consulting Fee: $37K · Honoraria: $18K · Food and Beverage: $12K.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $290,639.85 |
| Travel and Lodging | $81,648.77 |
| Consulting Fee | $37,007.55 |
| Honoraria | $17,880.00 |
| Food and Beverage | $12,204.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $394,693.31 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $58,345.70 | 2023-2025 | Auvelity |
| E.R. Squibb & Sons, L.L.C. | $45,237.00 | 2024-2025 | Cobenfy |
| Teva Pharmaceuticals USA, INC. | $12,028.45 | 2021-2025 | Austedo Xr, Austedo Xr |
| Bioxcel Therapeutics, INC. | $4,633.60 | 2023 | Igalmi |
| Alkermes, INC. | $3,772.59 | 2021-2025 | Aristada, Lybalvi |
| Sumitomo Pharma America, INC. | $3,223.55 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $1,295.00 | 2021-2023 | Trintellix |
| Sage Therapeutics, LLC | $964.00 | 2024 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $728.08 | 2021-2025 | Rexulti, Rejoyn |
| Abbvie INC. | $306.37 | 2023-2025 | |
| Neurocrine Biosciences, INC. | $239.70 | 2022-2024 | Ingrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $138.11 | 2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $100.58 | 2024-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $31.18 | 2024 | Fanapt |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $29.82 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Moller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.